Search

Your search keyword '"Birte Andritzky"' showing total 6 results
Start Over Author "Birte Andritzky" Journal onkologie
6 results on '"Birte Andritzky"'

1. Inhalt Band 32, 2009

Author

Michael Pfreundschuh, Susanne Albrecht, Gunter Schuch, Thomas Hany, Wolfgang Schmitt, Thorsten Fischer, Martin Pölcher, Qingyuan Zhang, Michael Zünd, Niels Murawski, George H. Sakorafas, Karl T.M. Schneider, Sabine Balmer-Majno, Wenjie Ma, Jingxuan Wang, Ina Thöm, Nikolaus de Gregorio, Spiros Christodoulou, Thomas Kubin, Christos Lappas, Rolf Kreienberg, Isabell Witzel, Shu Zhao, Egbert Nitzsche, Zhengyan Yu, Christine Wulff, Carsten Bokemeyer, Peter Brauchli, Antonia Dimitrakopoulou-Strauss, Clemens Caspar, Dieter Köberle, Gisela Walgenbach-Bruenagel, Michael Braun, Roger von Moos, Corinne Cescato-Wenger, Thorleif Etgen, Bernd Klaeser, Ruediger Hein, Nikolaos Antoniou, Eva Wardelmann, Christian Rudlowski, Shi Jin, Reinhard Büttner, Eckart Laack, Thomas Ruhstaller, Hanne Stensheim, Athanasios N. Chalazonitis, Manuel Debald, Nina Gottschalk, Ludwig G. Strauss, Flora Zagouri, Claudia Rogers, Meletios-Athanasios Dimopoulos, Aristotle Bamias, Jan C. Schuller, Maria Papaefthimiou, Birte Andritzky, Tobias Höller, Volker R. Jacobs, Bernhard C. Pestalozzi, Walther Kuhn, Stephanie Pildner von Steinburg, Georg Weidenhöfer, Axel Sauerwald, Lucas Widmer, Michael Safioleas, Matthias Wolfgarten, Yongzhi Zhuang, and Dieter K. Hossfeld

Subjects
Cancer Research, Oncology, Hematology, General Medicine
Published
2009
Full Text
View/download PDF

2. Contents Vol. 32, 2009

Author

Antonia Dimitrakopoulou-Strauss, Eckart Laack, Christine Wulff, Karl Schneider, Bernhard C. Pestalozzi, Eva Wardelmann, Hanne Stensheim, Maria Papaefthimiou, Birte Andritzky, Shu Zhao, Nikolaus de Gregorio, Michael Braun, Roger von Moos, Clemens B. Caspar, Athanasios N. Chalazonitis, Tobias Höller, Volker R. Jacobs, Niels Murawski, Spiros Christodoulou, Peter Brauchli, Yongzhi Zhuang, Susanne Albrecht, Nikolaos Antoniou, Jingxuan Wang, Wolfgang Schmitt, Zhengyan Yu, George H. Sakorafas, Nina Gottschalk, Flora Zagouri, Claudia Rogers, Michael Zünd, Axel Sauerwald, Carsten Bokemeyer, Aristotle Bamias, Thomas Kubin, Jan C. Schuller, Ruediger Hein, Corinne Cescato-Wenger, Dieter Köberle, Georg Weidenhöfer, Wenjie Ma, Gisela Walgenbach-Bruenagel, Dieter K. Hossfeld, Meletios-Athanasios Dimopoulos, Bernd Klaeser, Ludwig G. Strauss, Martin Pölcher, Isabell Witzel, Manuel Debald, Rolf Kreienberg, Ina Thöm, Sabine Balmer-Majno, Thorsten Fischer, Egbert Nitzsche, Christos Lappas, Shi Jin, Reinhard Büttner, Thorleif Etgen, Matthias Wolfgarten, Thomas F. Hany, Lucas Widmer, Michael Safioleas, Qingyuan Zhang, Stephanie Pildner von Steinburg, Gunter Schuch, Michael Pfreundschuh, Christian Rudlowski, Thomas Ruhstaller, and Walther Kuhn

Subjects
Cancer Research, Oncology, Hematology, General Medicine
Published
2009
Full Text
View/download PDF

3. Single-Center Management of 136 Patients with Cancer of Unknown Primary Site (CUP Syndrome) Over a Period of 10 Years

Author

Gunter Schuch, Dieter K. Hossfeld, Birte Andritzky, Ina Thöm, Claudia Rogers, Eckart Laack, Carsten Bokemeyer, and Isabell Witzel

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pediatrics, Single Center, Young Adult, Germany, medicine, Retrospective analysis, Humans, Longitudinal Studies, Aged, Aged, 80 and over, business.industry, Incidence, Cancer, Hematology, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Surgery, Survival Rate, Oncology, Cancer of unknown primary, Neoplasms, Unknown Primary, Female, business
Abstract

Cancer of unknown primary site (CUP syndrome) is a particular challenge in oncology which occurs in about 5-10% of cancer patients. Here, we investigated clinicopathological and prognostic factors in patients with CUP syndrome in a retrospective analysis.136 patients with CUP syndrome who were treated in our Department of Oncology and Hematology were analyzed over a period of 10 years. Clinical and histopathological characteristics, response to chemotherapy, survival and prognostic factors were investigated in a retrospective analysis.83 of the patients (61%) received first-line chemotherapy, which induced an overall response rate of 19%. Altogether 37 different chemotherapy regimens were used. Median overall survival of all patients was 7.9 months. In multivariate Cox regression analysis, gender, Karnofsky performance status, treatment modality and extent of disease were identified as independent prognostic factors.Our analysis showed a poor prognosis for patients with CUP syndrome. The response rate to chemotherapy was low with no significant benefit for any of the investigated cytotoxic agents. Newer diagnostic and therapeutical approaches might contribute to an improvement of prognosis, and their value is currently investigated in prospective studies.

Published
2009
Full Text
View/download PDF

4. Subject Index Vol. 32, 2009

Author

Susanne Albrecht, Michael Zünd, Nikolaus de Gregorio, Yongzhi Zhuang, Bernd Klaeser, Ludwig G. Strauss, Thomas Hany, Eckart Laack, Nina Gottschalk, Peter Brauchli, Egbert Nitzsche, Spiros Christodoulou, Axel Sauerwald, Rolf Kreienberg, Dieter Köberle, Matthias Wolfgarten, Gisela Walgenbach-Bruenagel, Zhengyan Yu, Gunter Schuch, Christine Wulff, Flora Zagouri, Claudia Rogers, Niels Murawski, Thorleif Etgen, Corinne Cescato-Wenger, Lucas Widmer, Karl T.M. Schneider, Jingxuan Wang, Eva Wardelmann, Michael Pfreundschuh, Michael Safioleas, Sabine Balmer-Majno, Wolfgang Schmitt, Hanne Stensheim, George H. Sakorafas, Thomas Kubin, Aristotle Bamias, Antonia Dimitrakopoulou-Strauss, Roger von Moos, Martin Pölcher, Christian Rudlowski, Ina Thöm, Georg Weidenhöfer, Dieter K. Hossfeld, Tobias Höller, Volker R. Jacobs, Clemens Caspar, Thomas Ruhstaller, Christos Lappas, Birte Andritzky, Stephanie Pildner von Steinburg, Walther Kuhn, Ruediger Hein, Bernhard C. Pestalozzi, Wenjie Ma, Maria Papaefthimiou, Isabell Witzel, Thorsten Fischer, Qingyuan Zhang, Shu Zhao, Michael Braun, Meletios-Athanasios Dimopoulos, Jan C. Schuller, Shi Jin, Reinhard Büttner, Athanasios N. Chalazonitis, Nikolaos Antoniou, Manuel Debald, and Carsten Bokemeyer

Subjects
Cancer Research, Index (economics), Oncology, Statistics, Subject (documents), Hematology, General Medicine, Mathematics
Published
2009
Full Text
View/download PDF

5. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)

Author

Christian R. Habermann, Manuela Anige, Gunter Schuch, Lutz Edler, Iris Burkholder, Stefan Brandl, Michael Görn, Ina Thöm, Dieter K. Hossfeld, Eckart Laack, Birte Andritzky, and Carsten Bokemeyer

Subjects
Oncology, Adult, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Cyclophosphamide, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Angiogenesis Inhibitors, Antineoplastic Agents, Pilot Projects, Docetaxel, Drug Administration Schedule, chemistry.chemical_compound, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Practice Patterns, Physicians', neoplasms, Survival rate, Survival analysis, Aged, Chemotherapy, Clinical Trials as Topic, business.industry, Hematology, General Medicine, Middle Aged, medicine.disease, Metronomic Chemotherapy, Survival Analysis, Trofosfamide, Survival Rate, Treatment Outcome, chemistry, Taxoids, business, therapeutics, medicine.drug
Abstract

The aim of this pilot study was to evaluate the efficacy and safety of a chemotherapy containing docetaxel and oral trofosfamide as a 'metronomic' secondline treatment of patients with metastatic non-small cell lung cancer (NSCLC).21 patients with stage IV disease NSCLC who had progressed under first-line chemotherapy were enrolled. Previous chemotherapy was platinum-based in 15 patients (71.4%), whereas 6 patients (28.6%) had received platinum-free combination chemotherapy. Patients received docetaxel 25 mg/m(2) on days 1, 8, and 15 every 4 weeks plus trofosfamide 50 mg per day.A total of 62 chemotherapy cycles were administered. The median number of cycles per patient was 3. The overall response rate to chemotherapy was 19%, median overall survival was 6.9 months, the median progression-free survival 2.9 months, the 1-year survival rate 28.6%, and the 2-year survival rate 7.1%. No grade IV toxicity was observed.Our results suggest that the combination of docetaxel and trofosfamide in a metronomic schedule is active and well tolerable as second-line therapy in patients with metastatic NSCLC. The concept of metronomic chemotherapy promises to be a valuable addition to the existing treatment options in NSCLC and warrants further investigation in phase III studies.

Published
2008

6. Bevacizumab – der neue Standard in der Darmkrebstherapie

Author

Pilar España, Iris Burkholder, Yesim Eralp, Helmut Prosch, Michael Hünerbein, Roberta Sarmiento, Michael Görn, Christian Fretz, Lars Påhlmann, Silke Gillessen, Gunter Schuch, Andreas Sommacal, Ai Lin Guo, Qing Zhou, Ina Thöm, Mariano Provencio, Chong Rui Xu, Monika Huber, Johannes Attems, Yi Long Wu, Thomas Cerny, Christian R. Habermann, Dieter K. Hossfeld, Adelaida Morales Umpierrez, Nina Dworan, Bernhard Gebauer, Basilio Martín Urcuyo, Antonio Sánchez, Peter M. Schlag, Zhen Wang, Guo Chun Zhang, Michael Töpfer, Catherine Rioufol, Wolfgang Schneider, Yasemin Ozluk, Lutz Edler, Arnoud J. Templeton, Birte Andritzky, Francisco Sicilia, Erkan Topuz, Stephan Koswig, Giampietro Gasparini, Ruth Espinosa, Manuela Anige, Bertrand Coiffier, Stefan Brandl, Nese Guney, Christine Armbruster, Jose Manuel Calvo-Villas, Robert Siegel, Stefan Dresel, Duygu Derin, Silvia Hofer, Carsten Bokemeyer, and Eckart Laack

Subjects
Cancer Research, Oncology, business.industry, Medicine, Hematology, General Medicine, business
Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results